Ensuring Safe Access to Mifepristone During the Pandemic and Beyond

Ann Intern Med. 2021 Jan;174(1):105-106. doi: 10.7326/M20-6671. Epub 2020 Oct 21.

Authors

Beatrice L Brown¹, Susan F Wood², Ameet Sarpatwari¹

Affiliations

¹ Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (B.L.B., A.S.).
² George Washington University Milken Institute School of Public Health, Washington, DC (S.F.W.).

Abstract

This article discusses the risk evaluation and mitigation strategy (REMS) program imposed by the Food and Drug Administration for mifepristone.

Publication types

Editorial

MeSH terms

Abortion, Induced / methods*
COVID-19 / epidemiology*
Female
Humans
Menstruation-Inducing Agents / pharmacology
Mifepristone / pharmacology*
Pandemics*
Pregnancy

Substances

Menstruation-Inducing Agents
Mifepristone